Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC) Abeer H. AbdelhafezBenjamin C. MusallGaiane M. Rauch Review 13 September 2020 Pages: 1 - 12
Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire Santosh K. SomasundaramShelley PotterJames Harvey Review 10 September 2020 Pages: 13 - 20
Width of margins in phyllodes tumors of the breast: the controversy drags on?—a systematic review and meta-analysis Arnaud ToussaintRomain Piaget-RosselPatrick Taffé Review 15 September 2020 Pages: 21 - 37
Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer Yuxiang LinLing LinHuali Shen Preclinical study 12 September 2020 Pages: 39 - 52
Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients Miryam YusufovMargo NathanHadine Joffe Preclinical study 12 September 2020 Pages: 53 - 62
The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype Satu TiainenKirsi RillaPäivi Auvinen Preclinical study Open access 18 September 2020 Pages: 63 - 72
Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer Lei XueFengju ChenSao Jiralerspong Preclinical study 17 September 2020 Pages: 73 - 84
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment Jiehui DengAatish ThennavanSylvia Adams Preclinical study 19 September 2020 Pages: 85 - 94
Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer Zahra MohamadzadeFrouzande MahjoubiBahram M. Soltani Preclinical study 24 September 2020 Pages: 95 - 106
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) Noam PondéDominique Agbor-TarhMartine Piccart Clinical trial 19 September 2020 Pages: 107 - 116
Factors associated with late-stage diagnosis of breast cancer among women in Addis Ababa, Ethiopia Alem GebremariamNebiyu DerejeAhmedin Jemal Clinical trial 18 September 2020 Pages: 117 - 124
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study Masato TakahashiShoichiro OhtaniNorikazu Masuda Clinical trial Open access 13 September 2020 Pages: 125 - 134
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer Otto Metzger FilhoAnita Giobbie-HurderErica L. Mayer Clinical trial 06 October 2020 Pages: 135 - 144
FDG-PET/CT in high-risk primary breast cancer—a prospective study of stage migration and clinical impact Marianne VogsenJeanette Dupont JensenMalene Grubbe Hildebrandt Clinical trial 12 September 2020 Pages: 145 - 153
Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis Soo Yeon BaekJisun KimSae Byul Lee Clinical trial 15 September 2020 Pages: 155 - 164
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer Shari B. GoldfarbVolkan TuranKutluk H. Oktay Clinical trial 15 September 2020 Pages: 165 - 173
Association between body mass index and localization of breast cancer: results from a nationwide inpatient database in Japan Takaaki KonishiMichimasa FujiogiHideo Yasunaga Clinical trial 19 September 2020 Pages: 175 - 182
Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer Elisa Van RaemdonckG. FlorisP. Neven Clinical trial 27 September 2020 Pages: 183 - 194
Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling Gregory S. CalipJohn KiddKent F. Hoskins Epidemiology 11 September 2020 Pages: 195 - 204
Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study Judy N. JacobseMichael SchaapveldFlora E. van Leeuwen Epidemiology 22 September 2020 Pages: 205 - 214
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center Katya LoskRachel A. FreedmanTari A. King Epidemiology 16 September 2020 Pages: 215 - 227
Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database Hannah Grace AbrahamYaoxuan XiaSofia Diana Merajver Epidemiology 08 October 2020 Pages: 229 - 238
Impact of patients’ refusal to undergo adjuvant treatment measures on survival H. MännleJ. W. SiebersK. Münstedt Epidemiology 24 September 2020 Pages: 239 - 246
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors Pietro SollenaVasiliki Nikolaouthe European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group Brief Report 10 September 2020 Pages: 247 - 253
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough? Michela PalleschiEmanuela ScarpiChiara Casadei Letter to the Editor 14 September 2020 Pages: 255 - 256
Telerehabilitation for patients with breast cancer through the COVID-19 pandemic Laura Ferreira de RezendeVinícius Emanoel FranciscoRicardo Laier Franco Letter to the Editor 10 September 2020 Pages: 257 - 259